Update of guidelines for the use of growth hormone in children: The lawson wilkins pediatric endocrinology society drug and therapeutics committee

Journal of Pediatrics

Volumn 143, Issue 4, 2003, Pages 415-421

  Wilson, Thomas A ^a   Rose, Susan R ^b   Cohen, Pinchas ^b   Rogol, Alan D ^b   Backeljauw, Philippe ^b   Brown, Rosalind ^b   Hardin, Dana S ^b   Kemp, Stephen F ^b   Lawson, Margaret ^b   Radovick, Sally ^b   Rosenthal, Stephen M ^b   Silverman, Lawrence ^b   Speiser, Phyllis ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HUMAN GROWTH HORMONE;

BRAIN PSEUDOTUMOR; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEMUR EPIPHYSIS; FOOD AND DRUG ADMINISTRATION; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; INTRACRANIAL HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCOLIOSIS; SHORT STATURE; SIDE EFFECT; TREATMENT INDICATION; TURNER SYNDROME;

EID: 0242270859     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0022-3476(03)00246-4     Document Type: Article

References (68)

1. Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Commitee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr 1995;6:857-67.
2. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000;85:3990-3.
3. Wyatt DT, Mark D, Slyper A. Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab 1995;80:3292-7.
4. Juul A, Bernasconi S, Clayton PE, Kiess W, DeMuinck-Keizer Schrama S. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res 2002;58:233-41.
5. Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: diagnosis of growth hormone deficiency. Growth Horm IGF Res 2001;11:137-65.
6. Loche S, Bizzarri C, Maghnie M, Faedda A, Tzialla C, Autelli M, et al. Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J Pediatr 2002;140:445-9.
7. Maghnie M, Salati B, Bianchi S, Rallo M, Tinelli C, Autelli M, et al. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone plus arginine in children and adults with congenital hypopituitarism. J Clin Endocrinol Metab 2001;86:1574-9.
8. Nagel BH, Palmbach M, Petersen D, Ranke MB. Magnetic resonance images of 91 children with different causes of short stature: pituitary size reflects growth hormone secretion. Eur J Pediatr 1997;156:758-63.
9. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379-81.
10. Nilsson AG. Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults. Horm Res 2000;54(Suppl 1):52-7.
11. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54:137-54.
12. Colao A, di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002;87:1088-93.
13. Biller BM, Vance ML, Kleinberg DL, Cook DM, Gordon T. Clinical and reimbursement issues in growth hormone use in adults. Am J Manag Care 2000;6:S817-27.
14. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;125:873-82.
15. Hauffa BP. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paediatr Suppl 1997;423:63-5.
16. Eiholzer U, l'Allemand D. Growth hormone normalises height, prediction of final height, and hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 2000;53:185-92.
17. Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Gasser T, Ellis K. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Horm Res 2000;53:200-6.
18. l'Allemand D, Eiholzer U, Schlumpf M, Steinert H, Riesen W. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. Eur J Pediatr 2000;159:835-42.
19. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5.
20. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999;84:3064-70.
21. Ranke MB, Lindberg A. Growth hormone treatment of short' children born small for gestational age or with Silver-Russell syndrome: results from KIGS (Kabi International Growth Study), including the first report on final height. Acta Paediatr Suppl 1996;417:18-26.
22. Stanhope R. Growth hormone treatment of short stature due to intrauterine growth retardation. Clin Endocrinol (Oxf) 2000;53:665-6.
23. de Zegher F, Albertsson-Wikland K, Wollmann HA, Chatelain P, Chaussain JL, Lofstrom A, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 2000;85:2816-21.
24. de Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D. High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pre-treatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab 2002;87:148-51.
25. Carel JC, Chatelain P, Rochiccioli P, Chaussain JL. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab 2003;88:1587-93.
26. Food and Drug Administration. FDA approves humatrope for short stature. 2003. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01242.html.
27. Wit JM, Rekers-Mombarg LT, Crowe BJ, Roberts K, Gill AM, Attanasio AF. Growth hormone (GH) significantly increases final height in patients with non-GH deficient short stature [abstract]. Pediatr Res 2003;53:154.
28. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn's disease [see comments]. N Engl J Med 2000;342:1633-7.
29. Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127-35.
30. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998;83:403-9.
31. Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998;83:2824-9.
32. Sackey A, Taylor CF, Barraclough M, et al. Growth hormone as a nutritional adjunct in cystic fibrosis. J Hum Nutr Diet 1995;8:185-91.
33. Huseman CA, Colombo JL, Brooks MA, Smay JR, Greger NG, Sammut PH, et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatr Pulmonol 1996;22:90-5.
34. Hardin DS, Stratton R, Kramer JC, Reyes de la Rocha S, Govaerts K, Wilson DP. Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Horm Metab Res 1998;30:636-41.
35. Alemzadeh R, Upchurch L, McCarthy V. Anabolic effects of growth hormone treatment in young chidren with cystic fibrosis. J Am Coll Clin Nutr 1998;17:419-24.
36. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001;139:636-42.
37. Hintz RL, Attie KM, Baptista J, Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group [see comments]. N Engl J Med 1999;340:502-7.
38. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Ross JL, Quigley CA, et al. Effect of growth hormone treatement on the final height of children with non-growth hormone-deficient short stature: a randomized, double-blind, placebo-controlled trial. Pediatr Res 2001;49:17A,#OR9-96.
39. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868-70.
40. Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy - a review. Growth Horm IGF Res 2000;10:306-17.
41. Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995;126:996-9.
42. Malozowski S, Green L. Premature thelarche in girls following growth hormone therapy. J Pediatr 2001;138:449.
43. Seminara S, Merello G, Masi S, Filpo A, La Cauza F, D'Onghia G, et al. Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Clin Endocrinol (Oxf) 1998;49:125-30.
44. Bourguignon JP, Pierard GE, Ernould C, Heinrichs C, Craen M, Rochiccioli P, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993;341:1505-6.
45. Pierard GE, Pierard-Franchimont C, Nikkels A, Nikkels-Tassoudji N, Arrese JE, Bourguignon JP. Naevocyte triggering by recombinant human growth hormone. J Pathol 1996;180:74-9.
46. Wyatt D. Melanocytic nevi in children treated with growth hormone. Pediatrics 1999;104:1045-50.
47. Zvulunov A, Wyatt DT, Laud PW, Esterly NB. Lack of effect of growth hormone therapy on the count and density of melanocytic naevi in children. Br J Dermatol 1997;137:545-8.
48. Fine RN, Sullivan EK, Kuntze J, Blethen S, Kohaut E. The impact of recombinant human growth hormone treatment during chronic renal insufficiency on renal transplant recipients. J Pediatr 2000;136:376-82.
49. Nishi Y, Tanaka T, Takano K, Fujieda K, Igarashi Y, Hanew K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab 1999;84:1961-5.
50. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000;10:297-305.
51. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4.
52. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, et al. Acromegaly, colonie polyps, and carcinoma. Clin Endocrinol (Oxf) 1997;47:17-22.
53. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002;360:273-7.
54. Sperling MA, Saenger PH, Ray H, Wilson TA, Rose SR. Growth hormone treatment and neoplasia-coincidence or consequence? J Clin Endocrinol Metab 2002;87:5351-2.
55. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87:3136-41.
56. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, et al. Increased mortality associated with growth hormone treatment in critically ill adults (see comments). N Engl J Med 1999;341:785-92.
57. Carroll PV, Van den Berghe G. Safety aspects of pharmacological GH therapy in adults. Growth Horm IGF Res 2001;11:166-72.
58. Eiholzer U, Nordmann Y, L'Allemand D. Fatal outcome of sleep apnea in PWS during the initial phase of growth hormone treatment. A case report. Horm Res 2002;58(Suppl 3):24-6.
59. Nordmann Y, Eiholzer U, l'Allemand D, Mirjanic S, Markwalder C. Sudden death of an infant with Prader-Willi syndrome - not a unique case? Biol Neonate 2002;82:139-41.
60. Gerard JM, Garibaldi L, Myers SE, Aceto T Jr, Kotagal S, Gibbons VP, et al. Sleep apnea in patients receiving growth hormone. Clin Pediatr (Phila) 1997;36:321-6.
61. Lindgren AC, Hellstrom LG, Ritzen EM, Milerad J. Growth hormone treatment increases CO(2) response, ventilation, and central inspiratory drive in children with Prader-Willi syndrome. Eur J Pediatr 1999;158:936-40.
62. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG, and The American Norditropin Clinical Trials. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002;87:90-8.
63. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High-dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc, Cooperative Study Group. J Clin Endocrinol Metab 2000;85:3653-60.
64. Ranke MB, Lindberg A, Chatelain P, Wilton P, Price DA, Albertsson-Wikland K, et al. The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Pharmacia International Growth Database. Horm Res 2001;55(Suppl 2):44-8.
65. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067-79.
66. Tauber M, Moulin P, Pienkowski C, Jouret B, Rochiccioli P. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment (see comments). J Clin Endocrinol Metab 1997;82:352-6.
67. Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 2001;86:1061-5.
68. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002;87:3650-5.